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A B S T R A C T
Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant
(autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients,
deﬁned as body mass index (BMI)  30 kg/m2. Dose adjustment was deﬁned as a reduction in standard dosing
 20%, based on ideal, reported dosing and actual weights. We included 2 groups of US patients who had received
autoHCT between 2008 and 2014. Speciﬁcally, we included patients with multiple myeloma (MM, n = 1696)
treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas (n = 781) who received
carmustine, etoposide, cytarabine, and melphalan conditioning. Chemotherapy dose was adjusted in 1324
patients (78%) with MM and 608 patients (78%) with lymphoma. Age, sex, BMI, race, performance score, comorbidity index, and disease features (stage at diagnosis, disease status, and time to transplant) were similar between
dose groups. In multivariate analyses for MM, adjusting for melphalan dose and for center effect had no impact on
overall survival (P = .894) and treatment-related mortality (TRM) (P = .62), progression (P = .12), and progressionfree survival (PFS; P = .178). In multivariate analyses for lymphoma, adjusting chemotherapy doses did not affect
survival (P = .176), TRM (P = .802), relapse (P = .633), or PFS (P = .812). No center effect was observed in lymphoma.
This study demonstrates that adjusting chemotherapy dose before autoHCT in obese patients with MM and lymphoma does not inﬂuence mortality. These results do not support adjusting chemotherapy dose in this population.
© 2018 American Society for Blood and Marrow Transplantation.

INTRODUCTION
Obesity incidence has been increasing steadily in recent
years [13]. The American Society of Clinical Oncology guidelines recommended chemotherapy dosing based on actual
body weight (ABW) for obese patients treated with curativeintent [4] chemotherapy in solid tumors. In contrast, hematopoietic cell transplantation (HCT) requires higher doses of
chemotherapy, and practices of adjusting the weight because
of concerns of organ toxicity are common [5,6]. In 2014 the
American Society for Blood and Marrow Transplant completed
an extensive review of the literature and published recommendations on chemotherapy dosing in obese patients [5].
That review focused on the effect of chemotherapy dosing on
survival and toxicity and included comparisons between obese
and nonobese patients. Yet, the recommendations were limited by the paucity of data in this population.
The complex clinical context of HCT, particularly allogeneic
HCT, makes it difﬁcult to isolate the impact of dose adjustment.
Autologous HCT is associated with low treatment-related mortality (TRM), but relapse remains the main cause of treatment
failure. The potentially lower “background noise” and more
uniform conditioning regimens across transplant centers make
autologous HCT a better setting for exploring the impact of
adjusted doses. Additionally, chemotherapy doses in autologous HCT are generally much higher than for standard cancer
treatment, so it is important to know whether obese patients
have a higher toxicity when doses are based on ABW.
Data from the Center for International Blood and Marrow
Transplant Research (CIBMTR) show that many, but not all,
transplant centers adjust chemotherapy dose for obese
patients, and dose-adjustment practices vary widely. This
study compares outcomes for obese patients whose chemotherapy dose was adjusted. Speciﬁcally, we compared outcomes for patients with multiple myeloma (MM) treated with
high-dose melphalan and patients with Hodgkin or nonHodgkin lymphomas who received carmustine, etoposide,
cytarabine, and melphalan (BEAM) conditioning.
METHODS
Data Sources
The CIBMTR is a working group of more than 500 transplantation centers
worldwide that contribute detailed data on HCT to a statistical center at the

Medical College of Wisconsin. The CIBMTR is a research collaboration
between the National Marrow Donor Program/Be The Match and the Medical
College of Wisconsin. Participating centers are required to report all transplantations consecutively; patients are followed longitudinally, and compliance is monitored by onsite audits. Data quality is ensured, both by
computerized checks for discrepancies and by physicians’ review of submitted data. The CIBMTR conducts observational studies and complies with all
applicable federal regulations that protect human subjects.
The CIBMTR collects data at 2 levels: Transplant Essential Data (TED) and
Comprehensive Report Form (CRF) data. TED-level data include disease, age,
sex, pre-HCT disease stage and chemotherapy responsiveness, date of diagnosis, graft type (bone marrow and/or blood-derived stem cells), conditioning
regimen, post-transplant disease progression and survival, development of a
new malignancy, and cause of death. All CIBMTR centers contribute TED-level
data. More detailed CRF-level data are collected on a subset of patients
selected by a weighted randomization scheme. TED- and CRF-level data are
collected pretransplant and then post-transplant at 100 days, at 6 months,
annually until year 6, and biannually thereafter until death. Data for the current analysis were retrieved from CIBMTR (TED and CRF) report forms.
Patients
Adult patients aged  18 years with a body mass index (BMI)  30 kg/m2
undergoing a ﬁrst autologous HCT for MM or lymphoma performed in US
centers between 2008 and 2014 were included in this study. BMI was calculated based on reported pretransplant actual weight and height. Additional
eligibility included only those patients with MM receiving a single-drug melphalan (200 mg/m2) conditioning regimen and only those with lymphoma
receiving a conditioning regimen with BEAM. The determination of chemotherapy dose reduction in patients with lymphoma receiving BEAM was
based on the actual dose of melphalan.
Study Design
This was a retrospective, registry-based study. To determine whether the
dose of chemotherapy had been adjusted, we looked at 3 possible measures:
pretransplant ABW, dosing weight (DW), and calculated ideal body weight
(IBW). We considered a patient to have received an adjusted dose if the DW
was <80% of ABW.
Two groups were deﬁned: (1) an unadjusted group, which dosed chemotherapy using actual weight, and (2) an adjusted group, which dosed chemotherapy using an adjusted weight based on the difference between IBW and
actual weight. The degree of adjustment (adjusted factor ß) varied across centers and was determined based on the following formula: DW = IBW + (adjusted
factor ß) £ (ABW  IBW). DW is the same as adjusted body weight used to calculate chemotherapy dosing. Because the biology and outcomes of MM and
lymphoma are signiﬁcantly different, we performed the analyses for the whole
group and separately for MM and lymphoma.
Endpoints and Deﬁnitions
As a surrogate for treatment-related toxicity, we used duration of hospitalization within the ﬁrst 100 days after HCT. The HCT-speciﬁc comorbidity
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index (HCT-CI) [7] was calculated excluding obesity. Because many centers
perform autologous HCT as an outpatient procedure or a hybrid, in which the
hospitalization is limited to the period when patients receive chemotherapy,
we considered only hospitalizations of >7 days.
TRM was deﬁned as any death in the absence of disease relapse or progression. Patients who died in the ﬁrst 28 days post-transplant without reported
disease relapse or progression were considered to have TRM. Relapse or progression was the competing risk for this event. Disease relapse or progression
was deﬁned by the transplant center either as morphologic or radiologic
relapse. For patients without relapse or progression information for whom the
reported cause of death was the primary disease, we considered them to have
relapse or progression, and the date was input as the day before the date of
death. TRM was the competing risk for this event. Progression-free survival
(PFS) was deﬁned as freedom from death, relapse, or progression of the disease
for which the patient received the autologous HCT. Living patients were censored at last follow-up. Overall survival (OS) was deﬁned as death from any
cause after HCT; living patients were censored at last follow-up.
Variables tested in the multivariate analyses were dose adjustment (main
effect), +age (18 to 49, 50 to 59, >60 years), sex, Karnofsky performance status (KPS) score (90% versus <90%), HCT-CI excluding obesity (0, 1 to 2, or
3), BMI (30 to 34, 35 to 39, or 40 kg/m2), year of transplant, and time from
diagnosis to HCT (<6, 6 to 12, 13 to 24, or >24 months). Additional diseasespeciﬁc variables included International Staging System [8] at time of diagnosis (I to II or III) and disease status at transplant (complete response, partial
response, or stable disease/progression) for MM and lymphoma subtype
(non-Hodgkin lymphoma or Hodgkin lymphoma) and prior chemotherapy
response (sensitive or resistant) for lymphoma.
Statistical Analysis
Patient-related and transplant-related factors were compared between
dose-adjusted and -unadjusted cohorts using the chi-square test for categorical variables and the Mann-Whitney test for continuous variables. The MannWhitney test was selected to accommodate continuous variables without
normal distribution. Probabilities for TRM and disease relapse were calculated, using cumulative incidence function accounting for competing risks
and compared using Gray’s test. PFS and OS were calculated using the
Kaplan-Meier estimator and compared using log-rank test.
Multivariate analysis of the 4 major outcomes were done using Cox
regression analysis, using the chemotherapy dose-adjustment covariate
as the main effect and forced in all models. The 4 outcomes were TRM,
disease progression or relapse, treatment failure, and overall mortality.
Each variable was tested for proportional hazard assumption. If assumption was violated, the variable was included as a time-dependent variable. To
identify the signiﬁcant risk factors, stepwise forward selection with a signiﬁcance level of .05 was used to deﬁne variables with a signiﬁcant association
with the outcome. Sensitivity analysis with signiﬁcance level of .1 was also
tested, which did not change the variables selected on the ﬁnal models. Interaction terms were examined between the chemotherapy dose-adjustment
covariate and other signiﬁcant covariates. Separate analyses were conducted
for patients with MM and lymphoma. Dose-adjustment practices were done
according to transplant center guidelines, which may result in a signiﬁcant
center effect, because individual cases cannot be considered independently.
Center effects were tested using the score test and adjusted using a marginal
model [9]. Analysis were done using SAS, version 9.4 (SAS Institute, Cary, NC).

RESULTS
Patients and Transplant Characteristics
Patient, disease, and transplant characteristics for patients
with MM (n = 1696) and lymphoma (n = 781) are summarized
in Table 1.
Among patients with MM, most patients had their melphalan
dose reduced (78%). The median age, sex, KPS score, HCT-CI, and
BMI were similar between the groups that had chemotherapy
adjusted or unadjusted. Disease characteristics including MM
stage, disease status at transplantation, median time from diagnosis to transplantation, and year of transplantation were also
similar between the 2 groups. The median adjustment factor for
melphalan was 25% (ie, the DW was the IBW plus 25% of the difference between IBW and ABW). Cytogenetic markers and
induction therapy were only available for a subgroup of patients
with CRF-level data (n = 1094) and were not considered.
Among patients with lymphoma, chemotherapy adjustment was done on 78% of patients. The groups of patients
whose chemotherapy was adjusted or unadjusted were similar
in terms of median age, sex, KPS score, HCT-CI, BMI, lymphoma

subtype, chemotherapy sensitivity before transplantation,
median time from diagnosis to transplantation, and year of
transplantation. Median chemotherapy adjustment factor
based on melphalan dosing in BEAM was 26%. In a subgroup of
patients with CRF-level reporting (n = 407), the distribution of
staging at diagnosis and number of prior lines of therapy were
similar between dose-adjustment groups.
Effect of Chemotherapy Adjustment on Length of Hospital
Stay
As a surrogate measure of treatment-related toxicity, the proportion of patients hospitalized > 7 days in the ﬁrst 100 days
post-transplantation was compared between the dose-adjustment groups. The length of hospitalization was available for
1042 patients with MM and 459 with lymphoma. Seventy-eight
percent of patients received dose-adjusted chemotherapy, with
a median length of hospitalization in the ﬁrst 100 days of
14 days (range, 8 to 72), in contrast to 15 days (range, 8 to 70) in
those with unadjusted chemotherapy dose (P = .20). A higher
proportion of patients with MM who received unadjusted doses
of chemotherapy had a hospital stay longer than 15 days (P =
.04). The same was not observed among patients with lymphoma (P = .59) (see Supplementary Table S1).
Effect of Chemotherapy Adjustment on Outcomes of All
Patients
To maximize the power to detect slight differences, the
impact of dose adjustment was tested on all patients, with
results shown in Figure 1 and summarized in Supplementary
Table S2. Multivariate analyses of overall mortality demonstrated a hazard ratio (HR) of 1.05 (95% conﬁdence interval
[CI], .89 to 1.24; P = .58). Younger age, KPS  90, HCT-CI < 3,
and chemotherapy-sensitive disease were independent predictors of lower mortality for the whole study population. There
was also no effect of dose adjustment on TRM (HR, 1.09; 95%
CI, .52 to 2.29; P = 0.83) and treatment failure (HR, .86; 95 CI,
.71 to 1.06; P = 0.16). Younger age, KPS  90, and a diagnosis of
myeloma were independent predictors of lower risk TRM. The
independent predictors of lower hazards of treatment failure
were female sex, KPS  90, chemotherapy-sensitive disease,
and disease. In contrast, there was a time-dependent effect of
chemotherapy dose adjustment on the risk of relapse: Patients
who received full-dose conditioning regimens had a 43% lower
relapse hazard within 5 months post-HCT (HR, .57; 95% CI, .37
to .89; P = .01) and similar relapse hazard thereafter (>5
months; HR, 1.0; 95% CI, .84 to 1.19; P = .96).
The impact of disease in the relapse model varied over time.
The relapse hazard for both diseases was the same in the ﬁrst 8
months post-HCT (HR, .98; 95% CI, .81 to 1.18; P = .79). However, after 8 months relapses were less common among
patients with lymphoma compared with MM (HR, .32; 95% CI,
.27 to .38; P < .01). Female sex and chemotherapy-sensitive
disease also independently predicted a lower hazard of relapse.
In addition, because chemotherapy adjustment varied by center, for patients with MM a statistically signiﬁcant center effect
was observed on TRM (P = .023), PFS (P < .001), and relapse
(P < .001) but not in survival (P = .66). For patients with lymphoma, no center effect was observed on any outcomes. The
causes of death were similar whether there were chemotherapy dose adjustments or not (Table 2).
Effect of Chemotherapy Adjustment on Outcomes of Patients
with MM
The 2-year OS probabilities were 88% (95% CI, 87% to 90%)
and 89% (95% CI, 85% to 92%; P = .92) and PFS were 45% (95% CI,
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Table 1
Patients and Transplant Characteristics of Obese Patients by DW
MM
Variable

Adjusted Weight

Actual Weight

Number of patients
Number of centers
Age, median, yr (range)
Male sex
Race
White
Black
Others
Not reported
KPS score  90%
HCT-CI
No comorbidity except obesity
1-2
3
Not reported
BMI kg/m2
Median (range)
30-34
35-39
40
DW adjusted factor ß, %*
Median (range)
<30%
30-79%
80-89%
90-100%
Disease
MM, IgG
MM, IgA
MM, IgD
MM, IgE
MM, IgM
MM, light chain
MM, nonsecretory
DLBCL
Follicular NHL
Mantle cell NHL
Other B cell NHL
T cell NHL
HL
MM stage at diagnosis
III
I-II
Not reported
MM status before HCT
Complete remission
Partial response
Stable/relapse/progression
Lymphoma status before HCT
Chemotherapy-sensitivey
Chemotherapy-resistantz
PIF/REL sensitivity unknown
Conditioning regimen
Melphalan dose, median, mg/kg (range)
Actual melphalan dose, median, mg (range)
Median time from diagnosis to transplant, mo (range)
Transplant year
2008-2010
2011-2012
2013-2014
Median follow-up of survivors, mo (range)

1324
103
58 (20-76)
747 (56)

372
69
58 (33-77)
210 (56)

954 (72)
322 (24)
22 (2)
26 (2)
753 (57)

245 (66)
115 (31)
5 (1)
7 (2)
202 (54)

518 (39)
414 (31)
390 (29)
2 (<1)

151 (41)
134 (36)
86 (23)
1 (<1)

34 (30-80)
768 (58)
342 (26)
214 (16)

34 (30-88)
240 (65)
82 (22)
50 (13)

25 (0-79)
888 (67)
376 (33)
0
0

100 (90-100)
0
0
52 (14)
320 (86)

784 (59)
266 (20)
7 (<1)
1 (<1)
8 (<1)
238 (18)
20 (2)

214 (58)
78 (21)
2 (<1)
0
4 (1)
64 (17)
10 (3)

Lymphoma
P

.66
.99
.08

.66
.12

Adjusted Weight

Actual Weight

609
74
55 (18-76)
380 (62)

172
51
55 (18-77)
102 (59)

512 (84)
78 (13)
12 (2)
7 (1)
378 (62)

148 (86)
21 (12)
2 (1)
1 (<1)
111 (65)

229 (38)
194 (32)
181 (30)
5 (<1)

76 (44)
48 (28)
48 (28)
0

34 (30-70)
333 (55)
146 (24)
130 (21)

34 (30-80)
102 (59)
39 (23)
31 (18)

26 (0-80)
326 (54)
283 (46)
0
0

100 (100)
0
0
0
172 (100)

P

.89
.46
.80

<.001
.28

.08

<.001

<.001

.70

.98

225 (37)
68 (11)
86 (14)
40 (7)
47 (8)
143 (23)

65 (38)
21 (12)
22 (13)
9 (5)
14 (8)
41 (24)

560 (92)
42 (7)
7 (1)

162 (94)
7 (4)
3 (2)

3 (2-8)
318 (179-1035)
16 (0-271)

3 (<1-10)
307 (26-962)
17 (1-180)

316 (52)
114 (19)
179 (29)
55 (2-110)

85 (49)
37 (22)
50 (29)
59 (1-101)

.01
655 (49)
595 (45)
74 (6)

185 (50)
180 (48)
7 (2)

206 (16)
966 (73)
152 (11)

69 (19)
266 (72)
37 (10)

.32

.34

4 (3-5)
436 (307-704)
8 (<1-183)

4 (2-5)
435 (163-619)
8 (3-763)

541 (41)
405 (30)
378 (29)
52 (1-103)

145 (39)
89 (24)
138 (37)
59 (2-101)

.06
.10
.17
.003

.84
.004
.87
.70

Values are n (%) unless otherwise deﬁned. DLBCL indicates diffuse large B cell lymphoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; PIF primary induction failure; REL, relapse.
* DW adjusted factor ß: adjusted DW = IBW + (adjusted factor ß) £ (ABW  IBW).
y
Chemotherapy-sensitive: complete remission, partial remission, relapse/progression or never in remission and sensitive to prior treatment immediately before
conditioning.
z
Chemotherapy-resistant: relapse/progression or never in remission and resistant to prior treatment immediately before conditioning.
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Figure 1. Multivariate analysis comparing unadjusted with adjusted doses of chemotherapy before autologous HCT for patients with MM, lymphoma, and all
patients. **In the combined population the effect of dose adjustment on disease relapse was signiﬁcant in the ﬁrst 5 months after transplant and not signiﬁcant
beyond 5 months.

42% to 48%) and 50% (95% CI, 45% to 55%; P = .08) for adjusted
and unadjusted groups, respectively (Figure 2). Corresponding
2-year cumulative incidences of disease progression were 54%
(95% CI, 51% to 56%) and 48% (95% CI, 43% to 53%; P = .002) and
of TRM were 1% (95% CI, 1% to 2%) and 2% (95% CI, 1% to 4%;
P = .29) (Figure 2). Multivariate analyses were carried out
adjusting for center effect on overall mortality (HR, 1.01; 95%
CI, .83 to 1.25; P = .89), treatment failure (HR, .85; 95% CI, .68 to
1.08; P = .1784), disease progression (HR, .84, 95% CI, .67 to
1.05; P = 0.12), and TRM (HR, 1.31; 95% CI, .45 to 3.79; P = .62)
of unadjusted compared with dose-adjusted chemotherapy
groups (Figure 1). Additional covariates associated with these
outcomes are shown on Supplementary Table S3.
Effect of Chemotherapy Adjustment on Outcomes of Patients
with Lymphoma
The 2-year OS probabilities were 79% (95% CI, 76% to 83%)
and 82% (95% CI, 75% to 87%; P = .51) and PFS were 59% (95% CI,
55% to 63%) and 61% (95% CI, 54% to 68%; P = .57) for adjusted
and unadjusted groups, respectively (Figure 3). Corresponding
2-year cumulative incidences of disease progression were 38%
Table 2
Causes of Death
Variable

Adjusted Body Weight

ABW

Number of patients
Number of deaths
Cause of death
Primary disease
Infection
Lung failure
Other organ failure
Other
Not reported

1933
622 (32%)

544
174 (32%)

465 (75%)
22 (4%)
9 (1%)
19 (3%)
57 (9%)
50 (8%)

129 (74%)
12 (7%)
1 (<1%)
6 (3%)
18 (10%)
8 (5%)

(95% CI, 34% to 42%) and 34% (95% CI, 27% to 41%; P = .35) and of
TRM were 3% (95% CI, 2% to 5%) and 5% (95% CI, 2% to 9%; P = .42)
(Figure 3). Multivariate analyses were carried out on overall
mortality (HR, 1.23; 95% CI, .91 to 1.66; P = .176), treatment failure (HR, 1.03; 95% CI, .81 to 1.30; P = .812), disease progression
(HR, 1.06; 95% CI, .83 to 1.36; P = .633), and TRM (HR, .91; 95% CI,
.44 to 1.90; P = .802) of unadjusted compared with adjusted chemotherapy groups (Figure 1). Additional covariates associated
with these outcomes are shown on Supplementary Table S3.
DISCUSSION
High-dose chemotherapy with autologous HCT is the standard of care for patients with MM and subsets of lymphoma.
The active therapy in autologous HCT is the high dose of chemotherapy, whereas the autologous graft serves as a supportive measure to accelerate hematopoietic recovery. Thus,
chemotherapy dosing is critical.
Our study compares the effect of adjusted doses (or reducing the dose by using an adjusted body weight) to doses based
on actual weight among obese (BMI  30 kg/m2) patients
undergoing autologous HCT for MM and lymphoma. The
hypothesis of this study was that adjusting the conditioning
regimen chemotherapy dose would result in reduced regimenrelated toxicity and early mortality but would adversely affect
long-term outcomes because of worse disease control.
The main ﬁndings were that most obese patients received
dose-adjusted conditioning regimens, that adjusting doses did
not appear to inﬂuence regimen-related toxicity, and that using
actual weight to dose high-dose chemotherapy before HCT did
not worsen OS in patients with either MM or lymphoma.
Single-center reports also found no differences in survival
when comparing obese patients with MM [10] and lymphoma
[11] who received dose-adjusted conditioning regimens with
nonobese patient who received chemotherapy based on ABW.
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Figure 2. Outcomes of patients with MM after autologous HCT using actual (unadjusted) weight and adjusted weight to calculate chemotherapy doses. Log-rank P
values are shown in each panel. Outcomes include (A) TRM, (B) disease progression, (C) PFS, and (D) OS.

Figure 3. Outcomes of patients with lymphoma after autologous HCT using actual (unadjusted) weight and adjusted weight to calculate chemotherapy doses. Logrank P values are shown in each panel. Outcomes include (A) TRM, (B) disease progression, (C) PFS, and (D) OS.
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In contrast, a report of BEAM dosed on ABW for obese patients
found no adverse effect on outcomes as well [12]. However,
these are single-center studies with smaller numbers of
patients and somewhat more uniform supportive care as compared with our registry-based study.
Our ﬁndings expand on a previous combined report from
European Society for Blood and Marrow Transplantation/
International Bone Marrow Transplant Registry that compared
the outcomes of obese patients with MM (BMI  30; n = 323)
with nonobese patients (n = 764) [13]. As in our study, most
obese patients received reduced doses of chemotherapy, and
there was no effect on mortality. In contrast to our study, however, patients who received a melphalan-only conditioning
regimen (n = 278) did not have increased rates of early relapse.
Albeit a small number (n = 45), obese patients who received a
conditioning regimen of melphalan with total body irradiation
(n = 45) had lower rates of relapse and mortality.
Additionally, our study showed that most obese patients with
MM or lymphoma (78%), notwithstanding American Society for
Blood and Marrow Transplant guidelines of melphalan dosing
[5], received adjusted doses. The prevalence of obesity (BMI  30
kg/m2) continues to increase in the general population [1,2]. The
Centers for Disease Control and Prevention report that 36.7% of
the US population is obese [3]. Concern over the most appropriate dosing strategy for the obese population led the American
Society for Blood and Marrow Transplant to issue a position
paper. However, paucity of data to inform the ﬁeld remains a
challenge [5]. The American Society of Clinical Oncology also
issued guidelines for dose adjustment for chemotherapeutic
agents [4], although these were not speciﬁc to transplant. The
main concern with the American Society of Clinical Oncology
guidelines was the frequent practice of underdosing chemotherapy in obese patients, resulting in worse control of disease. Historically, the use of IBW offers a simple way to approximate to
lean body, which is more cumbersome to estimate [14]. Also,
using lean body weight, or its surrogate, could be a safer way to
precisely predict the pharmacokinetics. However, pharmacokinetics and pharmacodynamics also are inﬂuenced by age, gender,
type of chemotherapy, and genetics, among other factors [46].
Even within the same chemotherapy the formulation needs to
be considered, because pharmacokinetic studies of substitute
captisol-stabilized for propylene glycol-free melphalan demonstrated a close to 10% increased systemic drug exposure compared with standard propylene glycolbased melphalan [15].
To better isolate the effect of chemotherapy dosing, the current study was limited to dosing strategies only in obese
patients undergoing autologous HCT. The dose-adjustment
strategy used varied depending on the transplant center, but
most centers adjust the dose of the conditioning regimen in
obese patients. This reﬂects the concerns of transplant physicians about the potential for increased toxicity of chemotherapy delivered based on ABW.
To assess the impact of conditioning regimen dose adjustment on toxicity in this study, the number of days hospitalized
in the ﬁrst 100 days post-HCT was used as a surrogate. Because
many centers only hospitalize autologous HCT recipients during the administration of the conditioning regimen and others
perform HCT as an outpatient procedure, we considered only
patients who spent more than 7 of the ﬁrst 100 days hospitalized. Overall, the length of hospitalizations was similar regardless of dose-adjustment strategy. However, when split by
disease, patients with MM who received doses based on actual
weight stayed longer in the hospital, based on a higher number
of patients with more than 15 days in the hospital. This was
mainly driven by the subset of patients with BMIs between 30

and 34 kg/m2, perhaps because this was the largest group. This
was not observed among patients with lymphoma. Our ﬁnding
contrasts with a single-center report on 80 patients. That
report observed longer hospitalizations and higher risks of
grades 3 to 4 mucositis in patients with lymphoma who
received a melphalan dose > 3.6 mg/kg [16]. One caveat on the
comparison of both studies is that melphalan is typically dosed
in mg/m2, and when the dose is converted to mg/kg patients
who are underweight rather than overweight are more frequently over the proposed threshold of 3.6 mg/kg.
The ideal assessment of regimen-related toxicity in autologous HCT would include detailed gastrointestinal side effects
(mucositis, diarrhea), need for total parenteral nutrition, and
infections. However, these were not available in the current
study.
Because disease biology, post-HCT treatment management,
autologous HCT goals, and treatment options at the time of disease relapse are different between MM and lymphoma, the
outcomes analysis was performed for all patients and then separately for each disease group. After adjusting for center effect,
there was no adverse effect of dose adjusting the conditioning
regimen on overall mortality, TRM, and treatment failure for
the entire population of the MM and lymphoma patient group
studied separately.
However, the higher risk of early relapse in those who
received dose-adjusted chemotherapy possibly reﬂects the
loss of intensity of the conditioning regimen on disease control. Considering that both MM and lymphoma have effective
salvage therapies, it is not unexpected that this increased risk
of early relapse does not affect overall mortality.
In summary, most obese patients undergoing autologous
HCT receive a dose-adjusted conditioning regimen. The
practice of reducing the dose of the conditioning regimen
in obese patients did not adversely affect mortality but did
result in an increased risk of early relapse after autologous
HCT. Thus, our ﬁndings do not support adjusting doses of
conditioning regimens for obese patients with MM or lymphoma.
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